PL1605939T3 - Zastosowanie farmaceutyczne 1-azabicyklo[2.2.2]oktanów i sposób testowania zdolności związków do aktywowania nieaktywnego wt p53 - Google Patents
Zastosowanie farmaceutyczne 1-azabicyklo[2.2.2]oktanów i sposób testowania zdolności związków do aktywowania nieaktywnego wt p53Info
- Publication number
- PL1605939T3 PL1605939T3 PL04723128T PL04723128T PL1605939T3 PL 1605939 T3 PL1605939 T3 PL 1605939T3 PL 04723128 T PL04723128 T PL 04723128T PL 04723128 T PL04723128 T PL 04723128T PL 1605939 T3 PL1605939 T3 PL 1605939T3
- Authority
- PL
- Poland
- Prior art keywords
- octanes
- azabicyclo
- inactive
- ability
- pharmaceutical use
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45652503P | 2003-03-24 | 2003-03-24 | |
SE0300812A SE0300812D0 (sv) | 2003-03-24 | 2003-03-24 | Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect |
PCT/SE2004/000452 WO2004084893A1 (en) | 2003-03-24 | 2004-03-24 | Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53 |
EP04723128A EP1605939B1 (en) | 2003-03-24 | 2004-03-24 | Pharmaceutical use of 1-azabicyclo¬ 2.2.2 octanes and a method of testing compounds for the ability of activating inactive wt p53 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1605939T3 true PL1605939T3 (pl) | 2009-04-30 |
Family
ID=33100505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL04723128T PL1605939T3 (pl) | 2003-03-24 | 2004-03-24 | Zastosowanie farmaceutyczne 1-azabicyklo[2.2.2]oktanów i sposób testowania zdolności związków do aktywowania nieaktywnego wt p53 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1605939B1 (pl) |
JP (1) | JP2006521375A (pl) |
AT (1) | ATE411020T1 (pl) |
AU (1) | AU2004224488B2 (pl) |
CA (1) | CA2519795A1 (pl) |
DE (1) | DE602004017146D1 (pl) |
DK (1) | DK1605939T3 (pl) |
ES (1) | ES2315650T3 (pl) |
NZ (1) | NZ542212A (pl) |
PL (1) | PL1605939T3 (pl) |
WO (1) | WO2004084893A1 (pl) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0400708D0 (sv) * | 2004-03-22 | 2004-03-22 | Aprea Ab | New compounds and use thereof |
US9061016B2 (en) | 2010-01-21 | 2015-06-23 | Aprea Ab | Aqueous solution comprising 3-quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease |
CN104860994A (zh) * | 2014-02-20 | 2015-08-26 | 中国药科大学 | 3-奎宁环酮类含磷化合物的制备及其医药用途 |
CN109280056A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 手性3-奎宁环酮类化合物、制备方法及用途 |
CN109280054A (zh) * | 2017-07-21 | 2019-01-29 | 上海时莱生物技术有限公司 | 氘代3-奎宁环酮类化合物、制备方法及用途 |
JP2022500471A (ja) | 2018-09-20 | 2022-01-04 | アプレア セラピューティクス アクティエボラーグ | キヌクリジン−3−オン化合物および癌治療へのその使用 |
AU2020349041A1 (en) | 2019-09-18 | 2022-04-28 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic Bcl-2 family protein |
WO2021170772A1 (en) | 2020-02-26 | 2021-09-02 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling |
WO2021180338A1 (en) | 2020-03-09 | 2021-09-16 | Aprea Therapeutics Ab | Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant |
WO2022175402A1 (en) | 2021-02-18 | 2022-08-25 | Aprea Therapeutics Ab | Quinuclidine-3-one derivatives |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921765B2 (en) * | 2000-09-20 | 2005-07-26 | Aprea Ab | 1-Azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors |
AU2003206329B2 (en) * | 2002-02-21 | 2007-08-09 | Aprea Therapeutics Ab | Use of low molecular weight compounds for preparing a medicament useful in treating mutant P53 mediated diseases |
-
2004
- 2004-03-24 PL PL04723128T patent/PL1605939T3/pl unknown
- 2004-03-24 NZ NZ542212A patent/NZ542212A/en unknown
- 2004-03-24 DK DK04723128T patent/DK1605939T3/da active
- 2004-03-24 WO PCT/SE2004/000452 patent/WO2004084893A1/en active Application Filing
- 2004-03-24 AT AT04723128T patent/ATE411020T1/de active
- 2004-03-24 ES ES04723128T patent/ES2315650T3/es not_active Expired - Lifetime
- 2004-03-24 DE DE602004017146T patent/DE602004017146D1/de not_active Expired - Lifetime
- 2004-03-24 JP JP2006507983A patent/JP2006521375A/ja active Pending
- 2004-03-24 EP EP04723128A patent/EP1605939B1/en not_active Expired - Lifetime
- 2004-03-24 CA CA002519795A patent/CA2519795A1/en not_active Abandoned
- 2004-03-24 AU AU2004224488A patent/AU2004224488B2/en not_active Expired
Also Published As
Publication number | Publication date |
---|---|
JP2006521375A (ja) | 2006-09-21 |
CA2519795A1 (en) | 2004-10-07 |
ATE411020T1 (de) | 2008-10-15 |
EP1605939B1 (en) | 2008-10-15 |
NZ542212A (en) | 2008-04-30 |
AU2004224488B2 (en) | 2009-09-10 |
WO2004084893A1 (en) | 2004-10-07 |
DK1605939T3 (da) | 2009-03-09 |
ES2315650T3 (es) | 2009-04-01 |
DE602004017146D1 (de) | 2008-11-27 |
EP1605939A1 (en) | 2005-12-21 |
AU2004224488A1 (en) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20055892L (no) | Karboksylsyrederivater | |
CA2367017A1 (en) | Inhibitors of impdh enzyme | |
WO2002058690A3 (en) | Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors | |
MY144992A (en) | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. | |
DE60112609D1 (en) | Pyrazolopyridine | |
MY120064A (en) | Indole derivatives as inhibitors or factor xa | |
WO2004005286A3 (en) | Viral inhibitors | |
MY131516A (en) | New indole derivatives as factor xa inhibitors | |
HK1057899A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
DE60043587D1 (de) | Mittel für erkrankungen assoziert mit knochensubstanzverlust | |
PL1605939T3 (pl) | Zastosowanie farmaceutyczne 1-azabicyklo[2.2.2]oktanów i sposób testowania zdolności związków do aktywowania nieaktywnego wt p53 | |
HK1087702A1 (en) | Arylmethylamine derivatives for use as tryptase inhibitors | |
NZ536750A (en) | 7-Aryl-3,9-diazabicyclo (3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases | |
AU2002239348A1 (en) | Pyrazolopyridine derivatives | |
WO2007021970A3 (en) | Stable pharmaceutical formulations and methods of use thereof | |
HUP0102515A2 (hu) | Ciklopeptidek, eljárás előállításukra, hatóanyagként azokat tartalmazó gyógyszerkészítmények és alkalmazásuk | |
PT1730144E (pt) | Compostos de 1,4,8-triaza-espiro[4.5]decan-2-ona substituídos | |
MY128840A (en) | Derivatives of 2-aminopyridines, their use as medicaments and pharmaceutical compositions containing them | |
AU5835400A (en) | Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and process for the preparation of the active substance | |
WO2000069424A3 (en) | Method of treating psychotic disorders | |
SE0300812D0 (sv) | Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect | |
IL172134A0 (en) | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders | |
WO2004056832A3 (en) | Epothilone derivatives | |
WO2001023385A3 (en) | Novel tropane analogs | |
WO2005039480A8 (en) | AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT |